| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q2 2024 | 65 | $3.92B | +$212M | -$140M | +$72.6M | T, VZ, SGOV, WFC, GSK | 13F-HR | 8/7/2024, 07:31 PM |
| Q1 2024 | 63 | $4B | +$472M | -$302M | +$169M | VZ, SGOV, T, WFC, UL | 13F-HR | 5/6/2024, 09:47 PM |
| Q4 2023 | 60 | $3.56B | +$187M | -$209M | -$22.2M | VZ, T, SGOV, WFC, GSK | 13F-HR | 2/8/2024, 05:28 PM |
| Q3 2023 | 59 | $3.21B | +$243M | -$163M | +$80.2M | SGOV, T, GSK, VZ, TTE | 13F-HR | 11/7/2023, 08:29 PM |
| Q2 2023 | 60 | $3.23B | +$327M | -$229M | +$97.9M | SGOV, VZ, GSK, WFC, T | 13F-HR | 8/2/2023, 06:47 PM |
| Q1 2023 | 57 | $3.05B | +$206M | -$94.7M | +$111M | T, VZ, GSK, INGR, META | 13F-HR | 5/3/2023, 09:34 PM |
| Q4 2022 | 56 | $2.97B | +$279M | -$216M | +$62.9M | T, TTE, VZ, INGR, GL | 13F-HR | 2/7/2023, 08:47 PM |
| Q3 2022 | 53 | $2.61B | +$298M | -$213M | +$85.1M | T, GL, WFC, TTE, INGR | 13F-HR | 11/9/2022, 02:54 PM |
| Q2 2022 | 56 | $2.7B | +$309M | -$243M | +$65.8M | GSK, T, VZ, TTE, INGR | 13F-HR | 8/8/2022, 04:36 PM |
| Q1 2022 | 59 | $2.93B | +$537M | -$470M | +$66.3M | T, GSK, VZ, WMB, DLTR | 13F-HR | 5/10/2022, 03:06 PM |
| Q4 2021 | 54 | $2.76B | +$232M | -$257M | -$24.6M | GSK, DLTR, VZ, WFC, GD | 13F-HR | 2/7/2022, 08:14 PM |
| Q3 2021 | 53 | $2.61B | +$61.7M | -$91.2M | -$29.6M | GSK, VZ, WFC, GD, T | 13F-HR | 11/15/2021, 09:56 AM |
| Q2 2021 | 53 | $2.66B | +$216M | -$190M | +$26.7M | GSK, VZ, WFC, WMB, AXP | 13F-HR | 8/6/2021, 11:15 AM |
| Q1 2021 | 52 | $2.52B | +$200M | -$149M | +$50.9M | VZ, GSK, HIG, WFC, USB | 13F-HR | 5/12/2021, 03:12 PM |
| Q4 2020 | 51 | $2.14B | +$174M | -$275M | -$101M | SCHW, GSK, VZ, HIG, USB | 13F-HR | 2/9/2021, 09:42 PM |
| Q3 2020 | 52 | $1.96B | +$200M | -$309M | -$109M | UPS, VZ, JNJ, GSK, SCHW | 13F-HR | 11/12/2020, 05:23 PM |
| Q2 2020 | 50 | $2.01B | +$143M | -$345M | -$202M | VZ, UPS, GSK, TFC, TRV | 13F-HR | 8/10/2020, 09:43 AM |
| Q1 2020 | 49 | $1.94B | +$333M | -$581M | -$248M | VZ, UPS, JNJ, GSK, TRV | 13F-HR | 5/11/2020, 12:21 PM |
| Q4 2019 | 53 | $2.91B | +$242M | -$271M | -$29M | SHV, GSK, USB, UPS, TFC | 13F-HR | 2/11/2020, 05:05 PM |
| Q3 2019 | 47 | $2.8B | +$200M | -$312M | -$111M | SHV, UPS, GSK, USB, KR | 13F-HR | 11/12/2019, 09:32 AM |
| Q2 2019 | 62 | $2.86B | +$131M | -$293M | -$162M | SHV, EBAY, USB, GSK, AXP | 13F-HR | 8/5/2019, 12:48 PM |
| Q1 2019 | 60 | $2.96B | +$247M | -$323M | -$76.5M | SHV, GSK, UPS, XOM, EBAY | 13F-HR | 5/7/2019, 04:48 PM |
| Q4 2018 | 65 | $2.77B | +$292M | -$258M | +$34.8M | SHV, VZ, GSK, USB, EXC | 13F-HR | 2/12/2019, 07:34 PM |
| Q3 2018 | 61 | $3.1B | +$235M | -$341M | -$106M | SHV, XOM, GSK, TGT, AXP | 13F-HR | 11/5/2018, 04:49 PM |
| Q2 2018 | 56 | $3.08B | +$158M | -$145M | +$12.3M | SHV, EXC, XOM, GSK, AXP | 13F-HR | 8/3/2018, 10:25 AM |
| Q1 2018 | 57 | $3.01B | +$485M | -$349M | +$136M | SHV, GSK, EXC, XOM, USB | 13F-HR | 5/7/2018, 12:25 PM |
| Q4 2017 | 58 | $3B | +$104M | -$212M | -$108M | EXC, EBAY, AXP, TGT, WFC | 13F-HR | 2/12/2018, 04:08 PM |
| Q3 2017 | 53 | $2.9B | +$83.3M | -$194M | -$111M | EBAY, WMT, EXC, AXP, PNC | 13F-HR | 11/9/2017, 08:22 PM |
| Q2 2017 | 46 | $2.93B | +$93.9M | -$299M | -$205M | WMT, EXC, EBAY, MDT, AXP | 13F-HR | 8/4/2017, 12:28 PM |
| Q1 2017 | 40 | $3.07B | +$243M | -$354M | -$111M | EBAY, EXC, WMT, XOM, GSK | 13F-HR | 5/9/2017, 04:51 PM |
| Q4 2016 | 42 | $3.11B | $0 | $0 | WMT, EXC, PEP, XOM, EBAY | 13F-HR | 2/2/2017, 07:55 AM |